Daunorubicin, Cytarabine, and Cladribine Regimen Plus Radiotherapy and Donor Lymphocyte Infusion for Extramedullary Relapse of Acute Myeloid Leukemia after Hematopoietic Stem Cell Transplantation. (27th August 2013)

• Record Type: Journal Article
• Authors: Sanna, Marco; Caocci, Giovanni; Vacca, Adriana; Piras, Eugenia; Orrù, Federica; La Nasa, Giorgio
• Other Names: Allsup D. J. Academic Editor.; Kawauchi K. Academic Editor.
• Is Part Of: Case reports in hematology. Volume 2013(2013)
• Publication Date: 2013-08-27
• Subjects: Hematology -- Periodicals; Hematology -- Case studies -- Periodicals; Blood -- Diseases -- Periodicals; Hematology; Hematologic Diseases; Blood -- Diseases; Hematology; Electronic journals; Periodicals; Case studies; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; 616.15
• DOI: 10.1155/2013/258028
• Languages: English
• ISSNs: 2090-6560

Abstract

Abstract : Myeloid sarcoma is a rare tumor consisting of myeloid blasts that involve anatomic sites outside the bone marrow. Fatal prognosis is inevitable in patients with extramedullary relapse after hematopoietic stem cell transplantation (HSCT), and no standard treatments are available yet. We report the first case of extramedullary relapse after HSCT treated with a combination of daunorubicin, cytarabine, and cladribine (DAC) regimen plus radiotherapy and donor lymphocyte infusion (DLI). This treatment induced a new and durable remission in our patient. The favorable toxicity profile and the reduced cost make this combination worthy of further investigations.